{"id":"W4390372702","doi":"10.1016/j.jtho.2023.12.023","title":"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"Eisai","keywords":"Pembrolizumab; Medicine; Lenvatinib; Internal medicine; Placebo; Adverse effect; Oncology; Randomized controlled trial; Nivolumab; Gastroenterology; Immunotherapy; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002848146,0.0003540041,0.002230078,0.0005083963,0.0001443429,0.00002659023,0.0001820411,0.0001388139,0.00009892907],"category_scores_gemma":[0.0002115766,0.0001863465,0.0004771721,0.0007007689,0.0004286284,0.0001688598,0.0000313505,0.0003594536,0.000003498507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003464235,"about_ca_system_score_gemma":0.001963886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000398416,"about_ca_topic_score_gemma":0.0003552868,"domain_scores_codex":[0.9966384,0.0002327575,0.001658675,0.0003196944,0.0006788002,0.000471646],"domain_scores_gemma":[0.9953762,0.00055344,0.002771711,0.0002613936,0.000810054,0.0002272048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9630945,0.002348451,0.0004046274,0.0009943621,0.001473992,0.0006024023,0.0006512986,0.00004154554,0.003702684,0.000004490664,0.0003816527,0.02630002],"study_design_scores_gemma":[0.9055939,0.06164135,0.00005142771,0.0008177522,0.003472319,0.003407035,0.0005272822,0.0005129936,0.0208457,0.00002628062,0.002878002,0.0002258922],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987362,0.0003802861,0.00245589,0.001931313,0.0003865913,0.007292063,0.00002504916,0.00004027483,0.0001265569],"genre_scores_gemma":[0.9900365,0.0002028343,0.006724988,0.0001483158,0.0004867976,0.0006250451,0.00006539335,0.00007524499,0.001634827],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05929291,"threshold_uncertainty_score":0.7598991,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09940783536830322,"score_gpt":0.4412411812161992,"score_spread":0.341833345847896,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}